Literature DB >> 24307795

Expression of hepatitis B virus 1.3-fold genome plasmid in an SV40 T-antigen-immortalized mouse hepatic cell line.

Xiu-Guang Song1, Peng-Fei Bian, Shu-Li Yu, Xiu-Hua Zhao, Wei Xu, Xue-Hui Bu, Xia Li, Li-Xian Ma.   

Abstract

AIM: To investigate the expression of the hepatitis B virus (HBV) 1.3-fold genome plasmid (pHBV1.3) in an immortalized mouse hepatic cell line induced by SV40 T-antigen (SV40T) expression.
METHODS: Mouse hepatic cells were isolated from mouse liver tissue fragments from 3-5 d old Kunming mice by the direct collagenase digestion method and cultured in vitro. The pRSV-T plasmid was transfected into mouse hepatic cells to establish an SV40LT-immortalized mouse hepatic cell line. The SV40LT-immortalized mouse hepatic cells were identified and transfected with the pHBV1.3 plasmid. The levels of hepatitis B surface antigen (HBsAg) and hepatitis B e antigen (HBeAg) in the supernatant were determined by an electrochemiluminescence immunoassay at 24, 48, 72 and 96 h after transfection. The expressions of HBsAg and hepatitis B c antigen (HBcAg) in the cells were investigated by indirect immunofluorescence analysis. The presence of HBV DNA replication intermediates in the transfected cells and viral particles in the supernatant of the transfected cell cultures was monitored using the Southern hybridization assay and transmission electronic microscopy, respectively.
RESULTS: The pRSV-T plasmid was used to immortalize mouse hepatocytes and an SV40LT-immortalized mouse hepatic cell line was successfully established. SV40LT-immortalized mouse hepatic cells have the same morphology and growth characteristics as primary mouse hepatic cells can be subcultured and produce albumin and cytokeratin-18 in vitro. Immortalized mouse hepatic cells did not show the characteristics of tumor cells, as alpha-fetoprotein levels were comparable (0.58 ± 0.37 vs 0.61 ± 0.31, P = 0.37). SV40LT-immortalized mouse hepatic cells were then transfected with the pHBV1.3 plasmid, and it was found that the HBV genome replicated in SV40LT-immortalized mouse hepatic cells. The levels of HBsAg and HBeAg continuously increased in the supernatant after the transfection of pHBV1.3, and began to decrease 72 h after transfection. The expressions of HBsAg and HBcAg were observed in the pHBV1.3-transfected cells. HBV DNA replication intermediates were also observed at 72 h after transfection, including relaxed circular DNA, double-stranded DNA and single-stranded DNA. Furthermore, a few 42 nm Dane particles, as well as many 22 nm subviral particles with a spherical or filamentous shape, were detected in the supernatant.
CONCLUSION: SV40T expression can immortalize mouse hepatic cells, and the pHBV1.3-transfected SV40T-immortalized mouse hepatic cell line can be a new in vitro cell model.

Entities:  

Keywords:  Hepatitis B virus 1.3-fold genome plasmids; Immortalized; Liposomes; Mouse hepatic cell; SV40 T-antigen; Transfection

Mesh:

Substances:

Year:  2013        PMID: 24307795      PMCID: PMC3848149          DOI: 10.3748/wjg.v19.i44.8020

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  32 in total

1.  Treatment options for chronic hepatitis. Antivirals look promising.

Authors:  A J Zuckerman; D Lavanchy
Journal:  BMJ       Date:  1999-09-25

2.  [Construction of recombinant eukaryotic expression plasmid containing 1.3-fold-overlength genome of HBV and its expression in HepG2 cells].

Authors:  Ni Tang; Ai-long Huang; Bing-qiang Zhang; Ge Yan; Ming-que Xiang; Dan Pu; Hui Guo
Journal:  Zhonghua Gan Zang Bing Za Zhi       Date:  2003-08

3.  Current status of antiviral therapy for hepatitis B.

Authors:  Daryl T-Y Lau; Wissam Bleibel
Journal:  Therap Adv Gastroenterol       Date:  2008-07       Impact factor: 4.409

4.  Inhibition of hepatitis B virus replication by shRNAs in stably HBV expressed HEPG2 2.2.15 cell lines.

Authors:  H Kayhan; E Karatayli; A R Turkyilmaz; F Sahin; C Yurdaydin; A M Bozdayi
Journal:  Arch Virol       Date:  2007-01-25       Impact factor: 2.574

5.  Complete nucleotide sequence of SV40 DNA.

Authors:  W Fiers; R Contreras; G Haegemann; R Rogiers; A Van de Voorde; H Van Heuverswyn; J Van Herreweghe; G Volckaert; M Ysebaert
Journal:  Nature       Date:  1978-05-11       Impact factor: 49.962

Review 6.  Therapy of chronic hepatitis B virus infection: inhibition of the viral polymerase and other antiviral strategies.

Authors:  F Zoulim
Journal:  Antiviral Res       Date:  1999-11       Impact factor: 5.970

7.  Characterization of elevated alanine aminotransferase levels during pegylated-interferon α-2b plus ribavirin treatment for chronic hepatitis C.

Authors:  Yo-Hei Aoki; Shogo Ohkoshi; Satoshi Yamagiwa; Masahiko Yano; Hiromichi Takahashi; Nobuo Waguri; Kentaro Igarashi; Soh-Ichi Sugitani; Toru Takahashi; Toru Ishikawa; Tomoteru Kamimura; Hiroto Wakabayashi; Toshiaki Watanabe; Yasunobu Matsuda; Minoru Nomoto; Yutaka Aoyagi
Journal:  Hepatol Res       Date:  2011-02       Impact factor: 4.288

8.  Long-term treatment with entecavir induces reversal of advanced fibrosis or cirrhosis in patients with chronic hepatitis B.

Authors:  Eugene R Schiff; Samuel S Lee; You-Chen Chao; Seung Kew Yoon; Fernando Bessone; Shun-Sheng Wu; Wieslaw Kryczka; Yoav Lurie; Adrian Gadano; George Kitis; Suzanne Beebe; Dong Xu; Hong Tang; Uchenna Iloeje
Journal:  Clin Gastroenterol Hepatol       Date:  2010-12-08       Impact factor: 11.382

9.  A role for both RB and p53 in the regulation of human cellular senescence.

Authors:  J W Shay; O M Pereira-Smith; W E Wright
Journal:  Exp Cell Res       Date:  1991-09       Impact factor: 3.905

10.  Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B.

Authors:  W G E Cooksley; T Piratvisuth; S-D Lee; V Mahachai; Y-C Chao; T Tanwandee; A Chutaputti; W Yu Chang; F E Zahm; N Pluck
Journal:  J Viral Hepat       Date:  2003-07       Impact factor: 3.728

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.